The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Senators questioned Novo Nordisk CEO Lars Jørgensen on Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs, which are cheaper in other countries. The CEO of ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...